Defence Therapeutics Inc.
DTCFF
$0.66
$0.047.21%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 339.50K | 770.20K | 438.30K | 243.10K | 248.60K |
| Depreciation & Amortization | 11.80K | 13.90K | 12.30K | 12.70K | 13.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 435.20K | 1.03M | 534.60K | 413.00K | 354.20K |
| Operating Income | -435.20K | -1.03M | -534.60K | -413.00K | -354.20K |
| Income Before Tax | -510.40K | -837.30K | -663.30K | -575.00K | -444.90K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -510.40K | -837.30K | -663.30K | -575.00K | -444.90K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -510.40K | -837.30K | -663.30K | -575.00K | -444.90K |
| EBIT | -435.20K | -1.03M | -534.60K | -413.00K | -354.20K |
| EBITDA | -428.30K | -1.02M | -522.20K | -405.10K | -341.20K |
| EPS Basic | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 54.73M | 54.71M | 49.21M | 46.20M | 45.54M |
| Average Diluted Shares Outstanding | 54.73M | 54.71M | 49.21M | 46.20M | 45.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |